PE20091106A1 - Vacuna - Google Patents

Vacuna

Info

Publication number: PE20091106A1
Authority: PE; Peru
Prior art keywords: adenoviric; appe; malaria; vector; protein
Prior art date: 2007-12-06

Application number

PE2008002018A

Other languages

English (en)

Spanish (es)

Inventor

Joseph D Cohen

Martine Marchand

Original Assignee

Glaxosmithkline Biolog Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-12-06

Filing date

2008-12-04

Publication date

2009-08-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091106(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-12-04 Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa

2009-08-24 Publication of PE20091106A1 publication Critical patent/PE20091106A1/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Tropical Medicine & Parasitology (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Biotechnology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Immunology (AREA)
Virology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Mycology (AREA)
Epidemiology (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Plant Pathology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicinal Preparation (AREA)

PE2008002018A 2007-12-06 2008-12-04 Vacuna PE20091106A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US99280207P	2007-12-06	2007-12-06

Publications (1)

Publication Number	Publication Date
PE20091106A1 true PE20091106A1 (es)	2009-08-24

Family

ID=40591828

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PE2008002018A PE20091106A1 (es)	2007-12-06	2008-12-04	Vacuna

Country Status (20)

Country	Link
EP (1)	EP2227550A2 (pt)
JP (1)	JP2011505796A (pt)
KR (1)	KR20100108544A (pt)
CN (1)	CN101939438A (pt)
AR (1)	AR069568A1 (pt)
AU (1)	AU2008333208A1 (pt)
BR (1)	BRPI0819889A2 (pt)
CA (1)	CA2707245A1 (pt)
CL (1)	CL2008003614A1 (pt)
CO (1)	CO6300795A2 (pt)
CR (1)	CR11537A (pt)
DO (1)	DOP2010000164A (pt)
IL (1)	IL205953A0 (pt)
MA (1)	MA32003B1 (pt)
MX (1)	MX2010006207A (pt)
PE (1)	PE20091106A1 (pt)
TW (1)	TW200938633A (pt)
UY (1)	UY31510A1 (pt)
WO (1)	WO2009071613A2 (pt)
ZA (1)	ZA201003851B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0815872D0 (en) *	2008-09-01	2008-10-08	Pasteur Institut	Novel method and compositions
GB201016471D0 (en) *	2010-09-30	2010-11-17	Isis Innovation	Viral vector immunogenic compositions
EA027236B1 (ru) *	2011-04-08	2017-07-31	Иммьюн Дизайн Корп.	Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа
CN110687289B (zh) *	2019-10-17	2023-04-18	中国人民解放军陆军军医大学	Fgl2蛋白作为疟疾感染标志物的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040136963A1 (en) *	2001-06-22	2004-07-15	The Trustees Of The University Of Pennsylvania	Simian adenovirus vectors and methods of use
JP5404990B2 (ja) *	2002-10-23	2014-02-05	グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム	マラリアに対するワクチン接種の方法
SG156535A1 (en) *	2002-12-17	2009-11-26	Crucell Holland Bv	Recombinant viral-based malaria vaccines
WO2005063805A1 (en) *	2003-12-23	2005-07-14	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antibodies against the amino terminus region of circumsporozoite protein prevent the onset of malaria infection
ATE449105T1 (de) *	2004-01-23	2009-12-15	Angeletti P Ist Richerche Bio	Impfstoffträger für schimpansen-adenovirus
EP1802336B1 (en) *	2004-10-14	2011-09-07	Crucell Holland B.V.	Malaria prime/boost vaccines
GB0513421D0 (en) *	2005-06-30	2005-08-03	Glaxosmithkline Biolog Sa	Vaccines
EP1998804B1 (en) *	2006-03-27	2014-04-16	Crucell Holland B.V.	Compositions comprising a recombinant adenovirus and an adjuvant
KR20090092752A (ko) *	2006-07-18	2009-09-01	글락소스미스클라인 바이오로지칼즈 에스.에이.	말라리아 백신
EP2998316B1 (en) *	2007-03-02	2019-06-12	GlaxoSmithKline Biologicals S.A.	Novel method and compositions
GB0706914D0 (en) *	2007-04-10	2007-05-16	Isis Innovation	Novel adenovirus vectors

2008
- 2008-12-04 AR ARP080105281A patent/AR069568A1/es not_active Application Discontinuation
- 2008-12-04 WO PCT/EP2008/066762 patent/WO2009071613A2/en not_active Ceased
- 2008-12-04 PE PE2008002018A patent/PE20091106A1/es not_active Application Discontinuation
- 2008-12-04 AU AU2008333208A patent/AU2008333208A1/en not_active Abandoned
- 2008-12-04 KR KR1020107014859A patent/KR20100108544A/ko not_active Withdrawn
- 2008-12-04 TW TW097147198A patent/TW200938633A/zh unknown
- 2008-12-04 MX MX2010006207A patent/MX2010006207A/es not_active Application Discontinuation
- 2008-12-04 EP EP08857977A patent/EP2227550A2/en not_active Withdrawn
- 2008-12-04 UY UY31510A patent/UY31510A1/es unknown
- 2008-12-04 CN CN2008801267101A patent/CN101939438A/zh active Pending
- 2008-12-04 BR BRPI0819889-6A patent/BRPI0819889A2/pt not_active IP Right Cessation
- 2008-12-04 CA CA2707245A patent/CA2707245A1/en not_active Abandoned
- 2008-12-04 JP JP2010536451A patent/JP2011505796A/ja active Pending
- 2008-12-04 CL CL2008003614A patent/CL2008003614A1/es unknown
2010
- 2010-05-25 IL IL205953A patent/IL205953A0/en unknown
- 2010-05-28 ZA ZA2010/03851A patent/ZA201003851B/en unknown
- 2010-06-02 DO DO2010000164A patent/DOP2010000164A/es unknown
- 2010-06-10 CO CO10070274A patent/CO6300795A2/es not_active Application Discontinuation
- 2010-06-29 CR CR11537A patent/CR11537A/es not_active Application Discontinuation
- 2010-07-05 MA MA32991A patent/MA32003B1/fr unknown

Also Published As

Publication number	Publication date
CN101939438A (zh)	2011-01-05
KR20100108544A (ko)	2010-10-07
CL2008003614A1 (es)	2010-01-15
MA32003B1 (fr)	2011-01-03
MX2010006207A (es)	2010-10-04
JP2011505796A (ja)	2011-03-03
ZA201003851B (en)	2012-11-28
UY31510A1 (es)	2009-08-03
DOP2010000164A (es)	2010-07-31
WO2009071613A2 (en)	2009-06-11
CR11537A (es)	2010-08-18
EP2227550A2 (en)	2010-09-15
AR069568A1 (es)	2010-02-03
CA2707245A1 (en)	2009-06-11
AU2008333208A1 (en)	2009-06-11
TW200938633A (en)	2009-09-16
WO2009071613A3 (en)	2009-08-13
IL205953A0 (en)	2010-11-30
CO6300795A2 (es)	2011-07-21
BRPI0819889A2 (pt)	2015-06-16

Publication	Publication Date	Title
EA201792562A1 (ru)	2018-05-31	Глюкагон и коагонисты гпп-1
MX2021011949A (es)	2021-11-03	Metodos para el tratamiento de enfermedad de higado graso no alcoholico y/o lipodistrofia.
AR050353A1 (es)	2006-10-18	Composicion de anticuerpo her2
MX2022012931A (es)	2022-11-08	Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5.
PE20091352A1 (es)	2009-09-16	Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas
ECSP10010697A (es)	2011-02-28	Inhibidores de dpp-iv para uso en el tratamiento de nafld
NI201100025A (es)	2011-11-02	Métodos de administración de las formulaciones tópicas antimicóticas para el tratamiento de las infecciones por hongos.
CO2016000671A1 (es)	2018-02-09	Construcciones de variantes de sirp-alfa y sus usos
MX2017003121A (es)	2017-08-02	Formulaciones de anticuerpos.
CL2008002361A1 (es)	2009-08-07	Uso de un antigeno derivado de la proteina circumesporozoito (cs) de plasmodium falciparum que se expresa en la etapa preeritrocitica de la infeccion por malaria para tratar bebes contra la malaria.
EA201890638A1 (ru)	2018-10-31	Отклоняющие кислоты, содержащие водорастворимое замедляющее действие средство, а также способы изготовления и применения
AR102547A1 (es)	2017-03-08	Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
PE20091106A1 (es)	2009-08-24	Vacuna
BR112017010832A2 (pt)	2017-12-26	composições de aminoácido para o tratamento de sintomas de doença
MX2021000516A (es)	2021-04-12	Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5.
AR099960A1 (es)	2016-08-31	Procedimientos y composición farmaceutica para inducir una respuesta inmunitaria
EA201001478A1 (ru)	2011-06-30	Вакцина
MX2019002248A (es)	2019-09-18	Proteina de union al factor h modificada.
PH12018501646A1 (en)	2019-05-27	Compositions and methods for treating infections
MX389042B (es)	2025-03-20	Uso de un extracto de proteina de levadura para estabilizar la turbiedad de la cerveza
AR073967A1 (es)	2010-12-15	Peptido-epitope rab6kifl/kif20a y vacunas que contienen al mismo
MX391376B (es)	2025-03-21	Composiciones de la membrana de la cáscara del huevo para usarse en el tratamiento de la cadena ligera kappa del factor nuclear de las células b activadas (nf-kb) en un organismo hospedero.
BRPI0508807A (pt)	2007-09-25	composição de tratamento capilar, uso de uma composição e método de tratamento de cabelo
EA201200538A1 (ru)	2012-11-30	Арабиногалактан для повышения приобретенного иммунного ответа
CO2019007671A2 (es)	2019-07-31	Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer

Legal Events

Date	Code	Title	Description
2013-05-31	FC	Refusal